Hamlet BioPharma AB ser. B (HAMLET-B.ST)
Hamlet BioPharma AB ser. B
BMC D10
Klinikgatan 32
Lund 222 42
Sweden
46 40 12 25 00
https://www.hamletpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 7
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Catharina Svanborg M.D. | Founder & Chairman of the Board | N/D | N/D | 1949 |
| Mr. Petter Segelman Lindqvist | Chief Executive Officer | N/D | N/D | N/D |
| Mr. Jakob Testad | Finance Director | N/D | N/D | N/D |
| Mr. Mats Persson | Executive Officer | N/D | N/D | 1961 |
Descripción
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company's products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer. The company was formerly known as Hamlet Pharma AB (publ) and changed its name to Hamlet BioPharma AB (publ) in August 2023. Hamlet BioPharma AB (publ) was incorporated in 1999 and is based in Lund, Sweden. Hamlet BioPharma AB (publ) is a subsidiary of Linnane Pharma AB.
Gestión corporativa
La calificación ISS Governance QuickScore de Hamlet BioPharma AB ser. B a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
